Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
about
FADD adaptor in cancerThe cancer stem cell: evidence for its origin as an injured autoreactive T cellImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammationThe role of astrocytes in CNS tumors: pre-clinical models and novel imaging approachesTumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression.The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes in health and disease.Apoptosis and CD95 ligand in immune privileged sites.Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilegeHuman FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions.Immature and neurally differentiated mouse embryonic stem cells do not express a functional Fas/Fas ligand system.Overview of cellular immunotherapy for patients with glioblastoma.Apoptosis and its clinical impact.Role of microglia in glioma biology.The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesisInduction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.Therapeutic activity of NK cells against tumors.Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.Mechanisms of malignant glioma immune resistance and sources of immunosuppressionHumoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape.All in the head: obstacles for immune rejection of brain tumours.Anemia in multiple myeloma: role of deregulated plasma cell apoptosis.Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancerFas ligand upregulation is an early event in colonic carcinogenesis.Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism.Immunotherapeutic strategies for malignant glioma.Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials.Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response.Cytokine gene therapy for malignant glioma.Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer.Programmed cell death of embryonic motoneurons triggered through the Fas death receptorOpposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis.T cell-tumor cell: a fatal interaction?Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice.Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM
P2860
Q24795895-4A23DFFA-089E-486A-BFF2-8C893D39A807Q25256839-ED96D869-86A4-4DA0-8E0C-FE1823FA71DBQ28078539-F569C665-8E79-4453-BDC4-FF3AF38F9044Q28298280-7A8E5789-53B4-4E61-ABCE-F93F5625AB04Q30618244-0F693F12-6CD6-4317-A479-8356D935C256Q33509284-32588091-62D1-48F5-A86D-54E8EB4F035EQ33782516-E71E7901-F942-494D-9C19-613F3A83AD5CQ33836317-EA264A82-9E49-4999-B958-C7034A501F7FQ33836347-DC1EF9E7-401D-4C69-8E25-ECEBB9648061Q33997713-5D83E223-F97D-4359-B41B-4D67800C807AQ34056050-4A3EF79F-B1C4-4871-8DCF-4BB2FFE8A696Q34182377-73C5FCF2-EB83-4420-8285-DF4EF12F7195Q34189694-B3DD97DE-51A5-4A41-801A-9AA288F1B0FEQ34214558-044F2AA9-31C3-47F2-B435-148AFBEB2C81Q34309564-B3BB3FC5-2920-4143-9F44-631463FD6721Q34411509-629F98D6-550B-4877-A31E-A2F2163A89BFQ34481479-F33431A6-26C8-4D1D-BF6F-A1E67E9BE66BQ34552162-FF91BBF7-DEA2-45EC-9E9D-FAFB1B0388BCQ34596741-9536DCB2-316D-4F8B-B812-49634FD9862CQ34661793-42CF6031-EA0A-438F-827A-D851C8D1FB56Q34769891-FDB437EB-F694-455D-94BD-38B6B99E09BAQ34842204-47A0FABD-EE67-4743-A40A-9962B2F0EE28Q34980347-CFFA0F4D-FCBB-41CD-84CE-1CECC4CCE0DAQ35354010-26373562-8715-455F-8E60-03D5AA1E6F8BQ35399449-0E76C052-7F62-46C6-BFD3-BF995ECBF2DBQ35678312-E3171043-ED50-444A-9A11-4EC328051B00Q35754052-2870BC26-A8F3-4B49-B4D6-E82483B27655Q35778576-0C33B979-5A9F-4392-846D-FE090A89F5D2Q35778581-BCBA0405-23A7-436A-AE9C-E9875ED39C1DQ35785971-D5BBB958-EF4A-422A-93DE-54B648CA36C8Q35801091-4124F5DB-70D2-4200-9472-885486845030Q35907022-F5C6DC5D-2062-4880-A529-D5D37FCFC217Q36250686-5C375052-EE59-4B3A-9EB0-A955AECBBD49Q36316322-5220AB0A-1EF3-40E6-A0B6-4FA301745369Q36368504-BE9B2C46-81A1-4043-BC03-C3F8F6D5E13AQ36380713-A3744098-244E-47DD-9A97-F6F51596536FQ36473831-A19AD743-BD92-43F7-BAB4-AD39030E068FQ36611112-B7B996F3-7B6E-4DAA-81B6-2BD899DAD3CFQ36643564-9BF08FB4-E8E9-4AC4-A34D-31174DD22A2CQ36839780-909E0A20-024E-4C7A-9678-3A7F63250B12
P2860
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1997
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
@en
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
@nl
type
label
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
@en
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
@nl
prefLabel
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
@en
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
@nl
P2093
P2860
P356
P1476
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
@en
P2093
A L Quiquerez
N de Tribolet
P R Walker
P Y Dietrich
V Schnuriger
P2860
P304
P356
10.1172/JCI119273
P407
P577
1997-03-01T00:00:00Z